Allergic Rhino-Conjunctivitis is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Allergic Rhino-Conjunctivitis have a 66.67% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Allergic Rhino-Conjunctivitis compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Allergic Rhino-Conjunctivitis overview

Allergic Rhino-Conjunctivitis is an allergen-induced inflammatory response mediated by IgE and most observed in children and most rare in children above 5 years and in adults. Allergens release by plants, herbs, pollens, animal dander, dust mites are common mediators. It is preferable to allergic rhinitis. The most common nasal symptoms are sneezing, irritability, itching, runny nose and non-nasal are redness, eye itching. Past or family history of allergens, physical symptoms like redness, nasal congestion, and laboratory findings skin prick test or IgE antibodies levels in blood are the diagnostics measures. Symptomatic care, treatment with antibiotics to prevent secondary infections, intranasal corticosteroids, antihistamines like cetirizine, levocetirizine for treating rhino conjunctivitis or runny nose. Antipyretic medications paracetamol, leukotriene receptor antagonist montelukast. The condition can be prevented by less exposure to known allergens, avoidance of cold foods.

For a complete picture of PTSR and LoA scores for drugs in Allergic Rhino-Conjunctivitis, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.